Survey results from Trier and Jena University show that in Saxony, Thuringia and Brandenburg democracy is in crisis. Most ...

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of ...

But amid the green energy boom, Ha’Kamwe’ is threatened by lithium exploration by the Australia-based company Arizona Lithium ...

The lab will study AI for quantitative finance, including research in financial markets and its microstructure, quantitative ...

RIT biomedical engineering faculty member discovers new micro-technique to differentiate disease-causing pathogens faster for ...

Supernus Pharmaceuticals Inc. (SUPN) announced a promising data from its exploratory open-label Phase 2a clinical study of SPN-820 in ...

The grant will support research into how climate change impacts human health — the single biggest health threat facing ...

Clarametyx is initiating the Phase 2a portion of a clinical trial on its novel antibody therapy CMTX-101 for cystic fibrosis-associated infections.

Phase 2a study demonstrated rapid and substantial decrease in depressive symptoms SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC ...

Nikon just announced the winners of the 2024 Nikon Small World Photomicrography Competition, where scientific microscope ...

Plasma exchange therapy, typically used to treat rare autoimmune disorders, is becoming a trendy longevity procedure. Here's ...

MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of ...